Biomed advances NA-931 into Phase 3 obesity trials

Biomed Industries unveiled global Phase 3 plans for NA-931 at the ADA 2026 Scientific Sessions in New Orleans, including testing the oral drug alone and with oral semaglutide. The program targets obesity and long-term weight maintenance as many patients stop GLP-1 treatment within a year.

Why it matters: - Obesity patients often stop GLP-1 drugs because of side effects, cost, access issues and weight regain after discontinuation. - Biomed is positioning NA-931 as a potential long-term maintenance option after GLP-1 therapy ends. - The company is also testing whether NA-931 can add to the weight-loss effects of oral semaglutide.

What happened: - Biomed Industries presented its global Phase 3 clinical protocol for NA-931 at the American Diabetes Association 86th Scientific Sessions in New Orleans, held June 5–18, 2026. - The presentation covered NA-931 both as a monotherapy and in combination with oral semaglutide for obesity. - Biomed is developing NA-931 as a 120 mg oral once-daily treatment. - Biomed expects to start Phase 3 enrollment after regulatory and operational readiness work is completed.

The details: - BIOCOMBO-1 is planned as a 68-week, randomized, double-blind, placebo-controlled, global Phase 3 study. - The study will evaluate NA-931 120 mg once daily alone. - The study will also evaluate NA-931 120 mg once daily with oral semaglutide 12.5 mg once daily. - The trial is expected to enroll about 466 adults without diabetes who are overweight or obese. - Eligibility includes a BMI of at least 30 kg/m², or at least 27 kg/m² with one obesity-related comorbidity. - The co-primary endpoints at Week 52 are percent change in body weight from baseline and the share of participants with at least 5% weight loss. - Key secondary endpoints include higher weight-loss thresholds, changes in BMI and waist circumference, IWQOL-Lite-CT Physical Function score, and other metabolic and cardiometabolic measures. - NA-931 is a first-in-class oral small-molecule quadruple receptor agonist targeting IGF-1, GLP-1, GIP and glucagon receptors. - The drug is designed to affect appetite regulation, energy expenditure, insulin sensitivity and lean body mass preservation. - In a 13-week Phase 2 multiple ascending dose study, NA-931 cut mean body weight by up to 13.8% at the 150 mg daily dose. - That result translated to an 11.9% placebo-adjusted reduction. - An exploratory analysis found up to 72% of NA-931-treated participants lost at least 12% of body weight after 13 weeks, compared with 1.9% on placebo. - The Phase 2 study identifier is NCT06564753. - Biomed says NA-931 has shown a favorable tolerability profile in studies completed to date.

Between the lines: - The trial design suggests Biomed wants to compete in both the weight-loss and maintenance segments of the obesity market. - Pairing NA-931 with oral semaglutide could help Biomed test whether a multi-pathway drug can extend or improve outcomes from existing GLP-1 treatment. - The company is leaning on persistence problems in GLP-1 therapy to make the case for a new chronic-care approach. - Forward-looking claims about therapeutic benefit and timelines remain contingent on trial results and regulatory execution.

What’s next: - Biomed will move into Phase 3 enrollment once readiness steps are finished. - The company will use the 52-week co-primary endpoints to assess whether NA-931 can deliver meaningful weight loss alone and in combination with oral semaglutide. - Biomed says the program is intended to support chronic weight management and maintenance after GLP-1 discontinuation. - More information is available in the company’s announcement.

The bottom line: - Biomed is betting that an oral quadruple agonist can both deepen weight loss and help patients keep the weight off after GLP-1 therapy stops.